Eculizumab biosimilar is a recombinant humanized monoclonal IgG2/4κ antibody produced by Chinese hamster ovary cell culture and purified by standard bioprocess technology. Eculizumab biosimilar contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculizumab biosimilaris composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.
Eculizumab biosimilar is supplied at a concentration of 10 mg/mL as a sterile, preservative-free, clear, colorless solution of pH 7.0, which contains 0.46 mg/mL sodium phosphate monobasic, 1.78 mg/mL sodium phosphate dibasic, 8.77 mg/mL sodium chloride, 0.22 mg/mL polysorbate 80 (vegetable origin).
Statement: this product is used for R&D only, not for clinical usage.
|
Name
|
Eculizumab biosimilar
|
|
CAS NO.
|
219685-50-4
|
|
Type
|
Whole antibody
|
|
Source
|
Humanized (from mouse)
|
|
Target
|
Complement protein C5
|
|
Clone
|
Monoclone
|
|
Molecular Weight
|
148 kDa
|
|
Antibody Form
|
Purified immunoglobulin
|
|
Physical Form
|
Solution
|
|
Grade Standard
|
Medicine Grade
|
|
Place of Origin
|
China (Mainland)
|
|
Storage
|
-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.
|
bio-equip.cn
中文
